Granted Patent
B2
US 12,290,527 · App. 18/412,414 · Granted May 6, 2025
Compositions and methods for reducing major thrombotic events in cancer patients
Inventors:
Jeffrey I. Zwicker (Boston, MA); Bruce Furie (Boston, MA); Jack Davis Stopa (Boston, MA); Robert Flaumenhaft (Boston, MA)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to methods for reducing soluble P-selectin and major thrombotic events in cancer patients.
Claims (18)
1. A method for reducing or preventing formation of a thrombus in a patient with cancer at increased risk for bleeding, with an elevated level of soluble P-selectin when compared to a reference or baseline level of soluble P-selectin, comprising administering to the patient a composition comprising an effective amount of isoquercetin, vitamin B3, and vitamin C, the effective amount of isoquercetin being about 500 mg per day,
comprising administrating the composition to the patient for a period of at least about 2 months;
wherein the patient does not exhibit primary venous thromboembolism after administration of the composition.
2. The method of claim 1 , wherein soluble P-selectin is decreased at least about 30% when compared to a reference or baseline level of soluble P-selectin, following administration of the isoquercetin.
3. The method of claim 1 , wherein soluble P-selectin decrease ranges from 30-40%, 40-50%, 55-60%, 60-70%, 70-75%, or 75-80% when compared to a reference or baseline level of soluble P-selectin, following administration of the isoquercetin.
4. The method of claim 1 , wherein the cancer is metastatic cancer.
5. The method of claim 4 , wherein the metastatic cancer is colorectal cancer, pancreatic cancer, or non-small cell lung cancer.
6. The method of claim 4 , wherein the metastatic cancer is selected from the group consisting of metastasizing forms of Hodgkin lymphoma, colorectal cancer, cervical cancer, lung cancer, skin cancer such as squamous cell cancer or basal cell carcinoma, head and neck cancer, gastric cancer, and pancreatic cancer.
7. The method of claim 1 , wherein the cancer is selected from the group consisting of estrogen receptor-dependent breast cancer, estrogen receptor-independent breast cancer, hormone receptor-dependent prostate cancer, hormone receptor-independent prostate cancer, brain cancer, renal cancer, glioblastoma, colon cancer, familial adenomatous polyposis (FAP), colorectal cancer, pancreatic cancer, bladder cancer, esophageal cancer, stomach cancer, genitourinary cancer, gastrointestinal cancer, uterine cancer, ovarian cancer, astrocytomas, gliomas, skin cancer, squamous cell carcinoma, Keratoakantoma, Bowen disease, cutaneous T-Cell Lymphoma, melanoma, basal cell carcinoma, actinic keratosis; ichtiosis; acne, acne vulgaris, sarcomas, Kaposi's sarcoma, osteosarcoma, head and neck cancer, small cell lung carcinoma, non-small cell lung carcinoma, leukemia, lymphomas and other blood cell cancers.
8. The method of claim 1 , wherein the patient exhibits no severe adverse events (grade 3 or 4 toxicities) during treatment.
9. The method of claim 1 , wherein the patient exhibits no primary venous thromboembolism (VTE) during treatment.
10. The method of claim 9 , wherein the patient exhibits no VTE for at least 30-60 days following treatment.
11. The method of claim 1 , wherein the patient exhibits no major hemorrhages during treatment.
12. The method of claim 1 , wherein the patient exhibits a decrease in platelet-dependent thrombin generation of from about 30-60% when compared to a reference or baseline level of platelet dependent thrombin, following administration of the isoquercetin.
13. The method of claim 1 , wherein the patient exhibits decreased D-dimer plasma concentration of about 20-30% when compared to a reference or baseline level of D-dimer plasma concentration, following administration of the isoquercetin.
14. The method of claim 1 , wherein the isoquercetin is administered in a composition comprising about 20 micrograms to about 3 grams of Vitamin B3, and optionally further comprises about 200 micrograms to about 3 grams of Vitamin C.
15. The method of claim 1 , further comprising administering between about 1000 micrograms to about 3000 micrograms of folic acid.
16. The method of claim 1 , wherein the patient exhibits increased PDI inhibition when compared to a reference or baseline level of PDI inhibition, following administration of isoquercetin.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 10, 2025
From: ZWICKER, JEFFREY I; FURIE, BRUCE; STOPA, JACK DAVIS; FLAUMENHAFT, ROBERT
To: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
Reel/Frame 069812/0954 →
Continuity (3)
Provisional Application
62773696
· Nov 30, 2018
References Cited (187)
US 4871718A
· Carniglia
· 1989
[cited by applicant]
US 5026721A
· Dudrick et al.
· 1991
[cited by applicant]
US 5578590A
· Grunicke et al.
· 1996
[cited by applicant]
US 5626884A
· Lockett
· 1997
[cited by applicant]
US 5804594A
· Murad
· 1998
[cited by applicant]
US 5846569A
· Anderson et al.
· 1998
[cited by applicant]
US 5948443A
· Riley et al.
· 1999
[cited by applicant]
US 6103756A
· Gorsek
· 2000
[cited by applicant]
US 6121249A
· Weissman et al.
· 2000
[cited by applicant]
US 6203818B1
· Vester
· 2001
[cited by applicant]
US 6210701B1
· Darland et al.
· 2001
[cited by applicant]
US 6261589B1
· Pearson et al.
· 2001
[cited by applicant]
US 6277426B1
· Reust
· 2001
[cited by applicant]
US 6277427B1
· Husz
· 2001
[cited by applicant]
US 6299925B1
· Xiong et al.
· 2001
[cited by applicant]
US 6352712B1
· Lukaczer et al.
· 2002
[cited by applicant]
US 6420142B1
· Buchholz et al.
· 2002
[cited by applicant]
US 6458406B1
· Ono et al.
· 2002
[cited by applicant]
US 6491948B1
· Buchholz et al.
· 2002
[cited by applicant]
US 6511675B2
· Siddiqui et al.
· 2003
[cited by applicant]
US 6514527B1
· Buchholz et al.
· 2003
[cited by applicant]
US 6514973B1
· Buchholz et al.
· 2003
[cited by applicant]
US 6541062B2
· Ono et al.
· 2003
[cited by applicant]
US 6551629B1
· Gorsek
· 2003
[cited by applicant]
US 6579544B1
· Rosenberg et al.
· 2003
[cited by applicant]
US 6616959B2
· Ono et al.
· 2003
[cited by applicant]
US 6683164B1
· Buchholz et al.
· 2004
[cited by applicant]
US 6812215B2
· Buchholz et al.
· 2004
[cited by applicant]
US 6821536B2
· Lines et al.
· 2004
[cited by applicant]
US 7009062B2
· Buchholz et al.
· 2006
[cited by applicant]
US 7041652B1
· Buchholz et al.
· 2006
[cited by applicant]
US 7182972B2
· Ono et al.
· 2007
[cited by applicant]
US 7270840B2
· Lines et al.
· 2007
[cited by applicant]
US 7588733B2
· Rich et al.
· 2009
[cited by applicant]
US 7943662B2
· Carola et al.
· 2011
[cited by applicant]
US 7960430B2
· Wirth et al.
· 2011
[cited by applicant]
US 8680053B2
· Lines
· 2014
[cited by applicant]
US 8840950B2
· Hibbert et al.
· 2014
[cited by applicant]
US 9987247B2
· Liu et al.
· 2018
[cited by applicant]
US 20020025350A1
· Siddiqui et al.
· 2002
[cited by applicant]
US 20030054357A1
· Young et al.
· 2003
[cited by applicant]
US 20030068391A1
· Harris et al.
· 2003
[cited by applicant]
US 20040101595A1
· Lines et al.
· 2004
[cited by applicant]
US 20060276393A1
· Milburn et al.
· 2006
[cited by applicant]
US 20070248590A1
· Milne et al.
· 2007
[cited by applicant]
US 20130028864A1
· Theoharides
· 2013
[cited by applicant]
US 20130129680A1
· Lines
· 2013
[cited by applicant]
US 20140350129A1
· Sikora et al.
· 2014
[cited by applicant]
US 20150366838A1
· Lines
· 2015
[cited by applicant]
US 20160041153A1
· Brown et al.
· 2016
[cited by applicant]
US 20160287591A1
· Lorence et al.
· 2016
[cited by applicant]
US 20190336473A1
· Lines
· 2019
[cited by applicant]
US 20220000835A1
· Lines
· 2022
[cited by applicant]
US 20240133897A1
· Zwicker et al.
· 2024
[cited by applicant]
CN 1507870A
· 2004
[cited by applicant]
CN 1562096A
· 2005
[cited by applicant]
CN 1706466A
· 2005
[cited by applicant]
CN 1715277A
· 2006
[cited by applicant]
CN 1895264A
· 2007
[cited by applicant]
CN 101554379A
· 2009
[cited by applicant]
CN 100581552C
· 2010
[cited by applicant]
CN 101623295A
· 2010
[cited by applicant]
DE 102006036307A1
· 2008
[cited by applicant]
JP 2002051732A
· 2002
[cited by applicant]
JP 2002293711A
· 2002
[cited by applicant]
JP 2006503896A
· 2006
[cited by applicant]
JP 2006507283A
· 2006
[cited by applicant]
WO 9841195A2
· 1998
[cited by applicant]
WO 2000012085A1
· 2000
[cited by applicant]
WO 200028986A1
· 2000
[cited by applicant]
WO 0207768A1
· 2002
[cited by applicant]
WO 2003007846A1
· 2003
[cited by applicant]
WO 2004037015A1
· 2004
[cited by applicant]
WO 2005095651A2
· 2005
[cited by applicant]
WO 2006076681A2
· 2006
[cited by applicant]
WO 2006084142A2
· 2006
[cited by applicant]
WO 2008011363A2
· 2008
[cited by applicant]
WO 2008011364A2
· 2008
[cited by applicant]
WO 2009025790A1
· 2009
[cited by applicant]
WO 2010078945A2
· 2010
[cited by applicant]
WO 2010119001A1
· 2010
[cited by applicant]
WO 2011042482A1
· 2011
[cited by applicant]
WO 2013036285A1
· 2013
[cited by applicant]
WO 2013055679A2
· 2013
[cited by applicant]
WO 2014070868A1
· 2014
[cited by applicant]
WO 2014111268A1
· 2014
[cited by applicant]
WO 2015125137A1
· 2015
[cited by applicant]
WO 2015196036A1
· 2015
[cited by applicant]
WO 2017027379A1
· 2017
[cited by applicant]
WO 2017083281A1
· 2017
[cited by applicant]
WO 2018170457A1
· 2018
[cited by applicant]
WO 2022023380A2
· 2022
[cited by applicant]
WO 2023288044A1
· 2023
[cited by applicant]
Ay, Blood, Oct. 1, 2008, vol. 112, No. 7, pp. 2703-2708. (Year: 2008).
[cited by examiner]
Mcmahon, Semin Thromb Hemost 2012; 38(08): 808-817. (Year: 2012).
[cited by examiner]
Sheth, Cardiovascular Diagnosis and Therapy, vol. 7, Suppl Dec. 3, 2017. (Year: 2017).
[cited by examiner]
Marshall et al. “Ambulatory therapy for thrombophlebitis with rutin and Vitamin C” Jul. 1950, American J. Surgery Paul Hoeber, New York, NY, US, 80(1):52-56, ISSN 0002-9610, XP026390130.
[cited by applicant]
Martin et al. “Role of Protein Disulfide Isomerase in Thrombus Formation in a Collagen-Induced Pathway of Thrombus Formation” 2010, Blood 116(21):1-6.
[cited by applicant]
Matsui et al. “Snake Venom Proteases Affecting Hemostasis and Thrombosis” Mar. 7, 2000, Biochimica et Biophysica Acta 1477, 146-156.
[cited by applicant]
Mcdowell et al. “Anthropometric Reference Data for Children and Adults: United States, 2003-2006” Oct. 22, 2008, National Health Statistics Reports, retrieved from the internet: https://www.cdc.gov/nchs/data/nhsr/nhsr01…
[cited by applicant]
Middleton et al. “The Effects of Plant Flavonoids on Mammalian Cells: Implications for Inflammation, Heart Disease and Cancer” Jan. 1, 2000, Pharmacological Reviews, American Society For Pharmacology and Experimental Th…
[cited by applicant]
Min et al. “The Chemistry and Medical Application of Tea Polyphenol” 2001, Hubei Chemical Industry 3:29-31.
[cited by applicant]
Nelson et al. “The Essential Medicinal Chemistry of Curcumin” Jan. 2017, J. Medicinal Chemistry 60:1620-1637.
[cited by applicant]
Oh et al. “Dual Roles of Quercetin in Platelets: Phosphoinositide-3-Kinase and MAP Kinases Inhibition, and cAMP-Dependent Vasodilator-Stimulated Phosphoprotein Stimulation” 2012, Evidence-Based Complementary and Alterna…
[cited by applicant]
Piergentili et al. “Bladder Cancer: Innovative Approaches Beyond the Diagnosis” May 2014, Current Medicinal Chemistry 21(20):2219-2236.
[cited by applicant]
Rakel “Integrative Medicine Second Ed.” 2007, Botanical supplements Elsevier Saunders, 313-316.
[cited by applicant]
Raymond et al. “Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors” 2011, The New England J. Medicine, 364(6):501-513.
[cited by applicant]
Razak et al. “Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment” Oct. 11, 2018, Cancers, 10(380):1-21, XP055836639.
[cited by applicant]
Saucier et al. “Synergetic Activity of Catechin and Other Antioxidants” 1999, Journal of Agricultural and Food Chemistry, 47(11):4491-4494.
[cited by applicant]
Sekeroglu et al. “
[cited by applicant]
Sesink et al. “Quercetin Glucuronides but Not Glucosides Are Present in Human Plasma After Consumption of Duercetin-3-Glucoside or Quercetin-4-Glucoside” 2001, Human Nutrition and Metabolism Research Communication, 1938…
[cited by applicant]
Shamay et al. “P-Selectin is a Nanotherapeutic Delivery Target in the Tumor Microenvironment” Jun. 29, 2016, Sci. Transl. Med. 8(345):1-28, DOI: 10.1126/scitranslmed.aaf7374.
[cited by applicant]
Spittle “The Action of Vitamin C on Blood Vessels” Sep. 1974, American Heart J. Smoking and Health Bulletin 88(3): 387-388.
[cited by applicant]
Staedler et al. “Drug Combinations with Quercetin: Doxorubicin Plus Quercetin in Human Breast Cancer Cells” Mar. 13, 2011, Cancer Chemotherapy and Pharmacology, SPRINGER, Berlin, Germany 68(5):1161-1172, DOI: 10.1007/S0…
[cited by applicant]
Thomas et al. “Ascorbate and Phenolic Antioxidant Interations in Prevention of Liposomal Oxidation” 1992, Lipids 27 (7):543-550.
[cited by applicant]
Trout “Vitamin C and Cardiovascular Risk Factors 1-3” 1991, American J. Clinical Nutrition, 53:322S-325S.
[cited by applicant]
Walle et al. “Quercetin Glucosides are Completely Hydrolyzed in Ileostomy Patients before Absorption” 2000, Human Nutrition and Metabolism Research Communication 2658-2661.
[cited by applicant]
Wells et al. “Value of Assessment of Pretest Probability of Deep-Vein Thrombosis in Clinical Management” 1997, The Lancet 350:1795-1798.
[cited by applicant]
Zangari et al. “Increased Risk of Deep-vein Thrombosis in Patients with Multiple Myeloma receiving Thalidomide and Chemotherapy” Sep. 1, 2001, Blood 98(5):1614-1615.
[cited by applicant]
Zhang et al. “Linking Inflammation and Thrombosis: Role of C-reactive protein” Nov. 26, 2010, World J. Cardiology 2(11):365-369.
[cited by applicant]
Zwicker et al. “Targeting Protein Disulfide Isomerase with the Flavonoid Isoquercetin to Improve Hypercoaqulability in Advanced Cancer” Feb. 21, 2019, JCI Insight 4(4):1-12, DOI: 10.1172/jci.insight.125851, ISSN: 2379-3…
[cited by applicant]
Zwicker et al. “Targeting Protein Disulfide Isomerase with the Oral Flavonoid Isoquercetin Prevents Venous Thromboembolism in Advanced Cancer: Results of a Multi-Dose, Multi-Center, Phase II Clinical Trial (CATIQ Study)…
[cited by applicant]
Canadian Office Action for application No. CA 3, 161,320 dated Oct. 7, 2024.
[cited by applicant]
Extended European Search Report and Written Opinion for EP 20897805.6 dated Jan. 23, 2024.
[cited by applicant]
Russian Office Action for application No. RU 2022118633 dated Sep. 20, 2024.
[cited by applicant]
Angst et al. “The Flavonoid Quercetin Inhibits Pancreatic Cancer Growth In Vitro and In Vivo” 2013, Pancreas 42(2):223-229.
[cited by applicant]
Baaten et al. “A synthesis Approach of Mouse Studies to Identify Genes and Proteins in Arterial Thrombosis and Bleeding” Oct. 1, 2018, Blood 132(24):35-46, XP055836634.
[cited by applicant]
Braga et al. “Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia” Jun. 1, 2021, Nature, 594(7861):1-43.
[cited by applicant]
Bucek et al. “C-reactive Protein in the Diagnosis of Deep Vein Thrombosis” 2002, British J. Haematology 119:385-389.
[cited by applicant]
Chou “Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies” 2006, Pharmacological Reviews 58:621-681.
[cited by applicant]
Chow et al. “Phase I Pharmacokinetic Study of Tea Polyphenols Following Single-dose Administration of Epigallocatechin Gallate and Polyphenon E1” Jan. 2001, Cancer Epidemiology, Biomarkers Prevention 10:53-58.
[cited by applicant]
Clinical Study NCT02195232 “Cancer Associated Thrombosis and Isoquercetin (CATIQ)” version 6 of Jan. 19, 2017, https://www.clinicaltrials.gov/study/NCT02195232?tab=historya=6.
[cited by applicant]
Cornuz et al. “Importance of Findings on the Initial Evaluation for Cancer in Patients with Symptomatic Idiopathic Deep Venous Thrombosis” 1996, Annals of Internal Medicine 125(10):785-793.
[cited by applicant]
Cortellaro et al. “The Plat Study: Hemostatic Function in Relation to Atherothrombotic Ischemic Events in Vascular Disease Patients” Sep. 1992, Principal results, Arteriosclerosis and Thrombosis 12(9):1063-1070.
[cited by applicant]
Crespy et al. “Quercetin, but not Its Glycosides, is Absorbed from the Rat Stomach” 2002, J. Agricultural and Food Chemistry 50:618-621.
[cited by applicant]
Dai et al. “Effects of Quercetin on Coagulation Function in Model Mice with Acute Lymphoblastic Leukemia” Jun. 27, 2018, J. Emergency in Traditional Chinese Medicine 27(6):970-973 (Chinese with full English translation).
[cited by applicant]
Di Lorenzo et al. “Complete Response and Fatigue Improvement With the Combined Use of Cyclophosphamide and Quercetin in a Patient with Metastatic Bladder Cancer” Feb. 2016, Medicine 95(5):1-4.
[cited by applicant]
Edwards et al. “Quercetin Reduces Blood Pressure in Hypertensive Subjects 1,2” 2007, The J. Nutrition 137:2405-2411.
[cited by applicant]
Erlund et al. “Pharmacokinetics of Quercetin from Quercetin Aglycone and Rutin in Healthy Volunteers” 2000, European J. Clinical Pharmacology 56:545-553.
[cited by applicant]
European Search Report and Written Opinion for EP 19891072.1 received Jul. 8, 2022, 17 Pages.
[cited by applicant]
European Search Report and Written Opinion for EP 21186637.1 received Dec. 3, 2021, 14 Pages.
[cited by applicant]
European Search Report and written opinion for EP15810201.2 received May 24, 2018, 17 Pages.
[cited by applicant]
Extended European Search Report for European Application No. 07799611.4, mailed Mar. 15, 2011, 4 Pages.
[cited by applicant]
Faes et al. “Red Blood Cells Modulate Structure and Dynamics of Venous Clot Formation in Sickle Cell Disease” Jun. 6, 2019, Blood 133(23):2529-2541.
[cited by applicant]
Feldman et al. “Intravascular Hemodynamic Factors Responsible for Progression of Coronary Atherosclerosis and Development of Vulnerable Plaque” 2000, Current Opinion in Cardiology 15:430-440.
[cited by applicant]
Fennerty “Venous Thromboembolic Disease and Cancer” 2006, Postgraduate Medical Journal 82:642-648.
[cited by applicant]
Gill et al. “Human C-Reactive Protein Increases Cerebral Infarct Size After Middle Cerebral Artery Occlusion in Adult Rats” 2004, J. Cerebral Blood Flow Metabolism 24:1214-1218.
[cited by applicant]
Guardia et al. “Anti-Inflammatory Properties of Plant Flavinoids, Effect of Rutin, Quercetin and Hesperidin on Adjuvant Arthritis in Rat” 2001, II Farmaco 56:683-687.
[cited by applicant]
Guo et al. “Subsequent Chemotherapy Reverses Acquired Tyrosine Kinase Inhibitor Resistance and Restores Response to Tyrosine Kinase Inhibitor in Advanced Non-Small-Cell Lung Cancer” 2011, BMC Cancer 11(90):5 Pages.
[cited by applicant]
Hamza et al. “Cancer-Associated Thrombosis: Risk Factors, Molecular Mechanisms, Future Management” Sep. 2020, Clinical and Applied Thrombosis/Hemostasis 26:1-13.
[cited by applicant]
Harwood et al. “A Critical Review of the Data Related to the Safety of Quercetin and Lack of Evidence of in Vivo Toxicity, including Lack of Genotoxic/Carcinogenic Properties” 2007, Food and Chemical Toxicology 45:2179-…
[cited by applicant]
Hermann et al. “Homocystein und B-Vitamine im Fokusvon Gefaeß- und neurodegenerativen Erkrankungen” Jun. 2011, Ernaehrung Und Medizin, Hippokrates Verlat Ins MVS Medizinverlage Stuttgart Gmgh Co. KG 26:62-74.
[cited by applicant]
Holbrook et al. “Zafirlukast is a broad-spectrum thiol isomerase inhibitor that inhibits thrombosis without altering bleeding times” 2021, British Pharmacological Society, 178:550-563.
[cited by applicant]
Ibrahiem et al. “Combined Cyclophosphomide Chemotherapy and Maltose Tetrapalmitate Immunotherapy in the Treatment of Transplanted Bladder and Prostate Carcinoma of the Rat” 1984, Cancer Research 44:536-542.
[cited by applicant]
Indap et al. “Tumour Response to Quercetin, A Bioflavonoid with Some Promises in Therapies” Sep. 2006, Indian J. of Pharmaceutical Sciences, India 68(5):570-574, DOI: 10.4103/0250-474X.29621, ISSN 0250-474X, XP055430202.
[cited by applicant]
International Search Report and Written Opinion for application No. PCT/US2023/083669 dated Jun. 21, 2024.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2007/073578 dated Jul. 11, 2008, 4 Pages.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2007/073580 dated Jul. 3, 2008, 4 Pages.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2015/036618 dated Sep. 16, 2015, 9 Pages.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2019/063328 dated Jan. 22, 2020, 11 Pages.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2020/064101 dated Mar. 4, 2021, 12 Pages.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2022/37259 dated Oct. 19, 2022.
[cited by applicant]
Invitation to Pay Additional Fees for Application No. PCT/IB2023/054726, dated Jul. 18, 2023.
[cited by applicant]
Japan Office Action for JP2009520941 dated Sep. 10, 2012, 3 Pages (English translation only).
[cited by applicant]
Kato, “Sickle Cells and Sickle Trait in Thrombosis” Jun. 6, 2019, Blood 133(23):2463.
[cited by applicant]
Katrin “Site-Specific Anticancer Effects of Dietary Flavonoid Quercetin” Dec. 30, 2013, Nutrition and Cancer, United States 66(2):177-193, DOI: 10.1080/01635581.2014.864418, ISSN 0163-5581, XP055473136.
[cited by applicant]
Kee et al. “Inhibitory Effect of Quercetin on Colorectal Lung Metastasis through Inducing Apoptosis, and Suppression of Metastatic Ability” Dec. 1, 2016, Phytomedicine, retrieved from the Internet: https://www.sciencedi…
[cited by applicant]
Koo et al. “Pharmacological Effects of Green Tea on the Gastrointestinal System” 2004, European J. Pharmacology, 500:177-184.
[cited by applicant]
Kountchev et al. “Reduction of D-Dimer Levels After Therapeutic Administration of Antithrombin in Acquired Antithrombin Deficiency of Severe Sepsis” 2005, Critical Care 9:596-600.
[cited by applicant]
Liu F et al. “Enhanced efficacy and reduced hepatotoxicity by combination of gnaphalium affine extract and benzbromarone in the treatment of rats with hyperuricemic nephropathy” 2021, Pharmaceutical Fronts, 3(3):e129-e1…
[cited by applicant]
Ma et al. “Creactive Protein (CRP) Rise is Associated with the Development of Acute Events in a Model of Plaque Rupture and Thrombosis” 2008, J. Life Science 5(2):21-24.
[cited by applicant]
Ma et al. “Growth Inhibitory Effects of Quercetin on Bladder Cancer Cell” 2006, Frontiers of Bioscience 11:2275-2285.
[cited by applicant]
Maclean et al. “Dicumarol and rutin in retinal vascular disorders” Sep. 1947, American J. Ophthalmology Elsevier, Amsterdam, NL, 30(9):1093-1108, ISSN 0002-9394, XP009184047.
[cited by applicant]
Mahan et al. “New antithrombotics: The impact on global health care” Mar. 29, 2011, Thrombosis Research Tarrytown, NY, US, 127(6):518-524, DOI: 10.1016/J.THROMRES.2011.03.022, ISSN 0049-3848, XP028219059.
[cited by applicant]
Malinow “Homocyst(e)ine, Vitamins and Genetic Interactions in Vascular Disease” Apr. 1999, Canadian J. Cardiology 15(Suppl B): 31B-34B.
[cited by applicant]